LONDON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback